ATRT-23. SMARCB1-DEPENDENCIES IN ATYPICAL TERATOID/RHABDOID TUMOURS: A STRATEGY FOR PRE-CLINICAL THERAPEUTIC TARGET IDENTIFICATION IN THE ABSENCE OF ACTIONABLE MUTATIONS

ATRTs have low mutation rates and few classically-actionable variants to direct molecularly targeted therapies; loss of SMARCB1 is the sole recurrent mutational event in >90% of ATRTs. We have designed and implemented a genome-scale strategy for target identification and prioritization in tumors...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Finetti, Martina Anna, Selby, Matthew p, Pons, Alicia del-Carpio, Batting, Sarah, Wood, James A, Barker, James M, Smith, Amanda, Crosier, Stephen, Bashton, Matthew, Pickles, Jessica C, Fairchild, Amy R, Avery, Aimee, O’Hare, Patricia, Pizer, Barry, Brennan, Bernadette, Lowis, Stephen, Hargrave, Darren, Jacques, Thomas S, Bailey, Simon, Clifford, Steven C, Williamson, Daniel
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6012497/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy059.021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados